臨床試驗

Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

NCT：NCT06790784 · RECRUITING

NCT IDNCT06790784

狀態RECRUITING

開始日期2025-08-04

SponsorJaeb Center for Health Research (OTHER)

First posted2025-01-24

Last updated2026-09-18

簡要摘要

This randomized trial will compare treatment strategies for proliferative diabetic retinopathy (PDR). Participants will receive either combination a of faricimab + PRP or vitrectomy + endolaser. The participants will be followed for 3 years. The study will evaluate long-term visual acuity as well as differences in number of injections, procedures, and complications during follow-up (after completion of randomization treatment), and cost.

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。